Drug combo not beneficial, could raise risks in diabetic nephropathy patients

11/13/2013 | PhysiciansBriefing.com

A study in the New England Journal of Medicine showed treatment with an ACE inhibitor plus angiotensin-receptor blocker did not fare better than monotherapy in reducing the risk of cardiovascular events and death in patients with diabetic nephropathy. Researchers also noted a higher likelihood of hyperkalemia and acute kidney injury in the combination therapy group compared with the monotherapy arm.

View Full Article in:

PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC